Philips appoints Ling Liu as Chief Region Leader of Philips Greater China
03 Juillet 2024 - 8:00AM
Philips appoints Ling Liu as Chief Region Leader of Philips Greater
China
July 3, 2024
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced the appointment of Ms Ling Liu as the Chief Region Leader
of Philips Greater China, effective immediately. Ms Liu is now a
member of Philips’ Executive Committee, reporting to Philips CEO
Roy Jakobs. She succeeds Andy Ho, who has decided to retire after a
long and successful career. Ms Liu and Mr Ho continue to work
together to ensure a smooth handover.
“Ling is a talented, trusted leader and I am delighted that she
will join Philips’ Executive Committee as the Chief Region Leader
of Philips Greater China,” said Roy Jakobs, CEO of Royal Philips.
“She is a proven executive who brings a wealth of international
experience and deep HealthTech expertise in China. I would also
like to express my deep gratitude to Andy for his exceptional
leadership in delivering on our commitment to supporting China’s
national health strategy and becoming a trusted partner for
professional customers as well as individual consumers. At the same
time as driving sustained financial and operational performance
over the last nine years.”
Ms Liu joined Philips in 1998 and has held multiple roles across
the business, living and working in Greater China, the Netherlands
and North America. Most recently, she was Chief Commercial Officer
in Greater China, following her role as Head of Finance for Philips
in North America. She has a track record of driving execution and
boosting performance, developing teams and delivering outstanding
value to customers and partners. She is passionate about delivering
quality care and contributing to sustainable healthcare in
China.
Ms Liu holds a master of finance and control from Maastricht
University, a master’s degree in management engineering from
Shanghai University, and a bachelor’s degree in physics from
Zhejiang University.
2023 marked the 100th anniversary of Philips in China, an
achievement that stands as a testament to Philips’ commitment and
dedication to improving people’s lives through meaningful
innovation and fostering strong partnerships in China. With
sustained growth and being Philips’ second largest market, it has
been one of the major growth engines for the company. Philips China
is focused on supporting China’s national health strategy,
supplying hospitals with solutions for their clinical and research
needs, and empowering consumers to manage their health and
well-being. With the aim of better serving the Chinese market,
Philips is committed to its ‘In China, For China’ strategy, which
focuses on local innovation, manufacturing, services and
partnership.
Additional information on Philips’ Executive Committee can be
found here.
For further information, please
contact:
Ben ZwirsPhilips External RelationsTel.: +31 6 1521 3446E-mail:
ben.zwirs@philips.com
Dorin DanuPhilips Investor RelationsTel.: +31 20 59 77055E-mail:
dorin.danu@philips.com
About Royal PhilipsRoyal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and well-being through meaningful
innovation. Philips’ patient- and people-centric innovation
leverages advanced technology and deep clinical and consumer
insights to deliver personal health solutions for consumers and
professional health solutions for healthcare providers and their
patients in the hospital and the home. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
ultrasound, image-guided therapy, monitoring and enterprise
informatics, as well as in personal health. Philips generated 2023
sales of EUR 18.2 billion and employs approximately 69,100
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
Forward-looking statementsThis release contains
certain forward-looking statements with respect to the financial
condition, results of operations and business of Philips and
certain of the plans and objectives of Philips with respect to
these items. Examples of forward-looking statements include
statements made about the strategy, estimates of sales growth,
future EBITA, future developments in Philips’ organic business and
the completion of acquisitions and divestments. By their nature,
these statements involve risk and uncertainty because they relate
to future events and circumstances and there are many factors that
could cause actual results and developments to differ materially
from those expressed or implied by these statements.
Koninklijke Philips NV (EU:PHIA)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Koninklijke Philips NV (EU:PHIA)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024